Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRIM24 | O15164 | 1/20 | 0.36 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 2/20 | 0.35 |
| ▸ | DRD4 | P21917 | 2/20 | 0.35 |
| ▸ | DRD3 | P35462 | 2/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.31 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.31 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.31 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.30 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4226883 | 0.68 | DRD2 (0.36) | DRD2DRD4DRD3HRH3 | |
| SCHEMBL4283522 | 0.68 | DRD2 (0.36) | DRD2DRD4DRD3HRH3 | |
| SCHEMBL2715907 | 0.68 | DRD2 (0.36) | DRD2DRD4DRD3HRH3 | |
| SCHEMBL4283523 | 0.68 | DRD2 (0.36) | DRD2DRD4DRD3HRH3 | |
| Hydrochloric Acid SCHEMBL31352065 | 0.67 | POLB (0.36) | DRD2DRD4DRD3ALDH1A1EGLN1 | |
| SCHEMBL10254093 | 0.67 | HTR2A (0.41) | DRD2DRD4DRD3KDM4EADRB2 | |
| SCHEMBL21067196 | 0.67 | EGLN2 (0.49) | — | |
| SCHEMBL22235731 | 0.65 | IRAK4 (0.42) | DRD2DRD4DRD3KDM4EADRB2 | |
| SCHEMBL30977579 | 0.65 | EGLN1 (0.32) | ALDH1A1EGLN1 | |
| SCHEMBL13239154 | 0.65 | FYN (0.32) | TRIM24TRIM33 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577243-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2026-03-17 | — | — | US | disclosed |
| WO-2025132870-A1 | CHEMICAL COMPOUNDS AND USES THEREOF | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.4) LIMITED (GB) | 2025-06-26 | — | — | WO | disclosed |
| US-12012411-B2 | Viral replication inhibitors | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2024-06-18 | — | — | US | disclosed |
| US-11820766-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| WO-2023180189-A1 | MPRO TARGETING ANTIVIRAL COMPOUNDS | EXSCIENTIA AI LIMITED (GB) | 2023-09-28 | — | — | WO | disclosed |
| US-20230145249-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-11 | — | — | US | disclosed |
| US-20220332713-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2022-10-20 | — | — | US | disclosed |
| US-20220106321-A1 | VIRAL REPLICATION INHIBITORS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2022-04-07 | — | — | US | disclosed |
| US-11279704-B2 | Viral replication inhibitors | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2022-03-22 | — | — | US | disclosed |
| EP-3541792-B1 | TRIAZOLE FURAN COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AMGEN INC (US) | 2020-12-23 | — | — | EP | disclosed |
| US-20140213586-A1 | VIRAL REPLICATION INHIBITORS | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2014-07-31 | — | — | US | disclosed |
| WO-2013045516-A1 | VIRAL REPLICATION INHIBITORS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2013-04-04 | — | — | WO | disclosed |
| US-7951799-B2 | sugar transport enhancement agent; antidiabetic and hypoglycemic agent; obesity, diabetic nephropathy, retinopathy, macrovascular disease, glucose tolerance anomaly; cyclization of 4-(2-aminocyclohexylamino)-3-pyrroline-2-one by aldehyde followed by acylation | AJINOMOTO CO., INC. (JP) | 2011-05-31 | — | — | US | disclosed |
| US-7951799-B2 | sugar transport enhancement agent; antidiabetic and hypoglycemic agent; obesity, diabetic nephropathy, retinopathy, macrovascular disease, glucose tolerance anomaly; cyclization of 4-(2-aminocyclohexylamino)-3-pyrroline-2-one by aldehyde followed by acylation | AJINOMOTO CO., INC. (JP) | 2011-05-31 | — | — | US | disclosed |
| US-20090318690-A1 | Benzisoxazole Compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-12-24 | — | — | US | disclosed |
| WO-2009095394-A1 | DIAZEPANES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC NEUROSCIENCES GMBH (DE) | 2009-08-06 | — | — | WO | disclosed |
| EP-2017275-A1 | BENZISOXAZOLE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2009-01-21 | — | — | EP | disclosed |
| US-20080108604-A1 | NOVEL LACTAM COMPOUND | AJINOMOTO CO., INC. (JP) | 2008-05-08 | — | — | US | disclosed |
| US-20080108604-A1 | NOVEL LACTAM COMPOUND | AJINOMOTO CO., INC. (JP) | 2008-05-08 | — | — | US | disclosed |
| EP-1878734-A1 | NOVEL LACTAM COMPOUND | Ajinomoto Co., Inc. (JP) | 2008-01-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220332713-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | TRIM24 4058/4885TRIM33 4330/4885DRD2 955/4885 |
| US-20080108604-A1 | NOVEL LACTAM COMPOUND | SLC2A4, SLC2A1, SLC2A9 | TRIM24 1471/4885TRIM33 1788/4885DRD2 3631/4885 |
| US-12577243-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, FAAH | TRIM24 4302/4885TRIM33 4595/4885DRD2 497/4885 |
| US-20230145249-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | TRIM24 4058/4885TRIM33 4330/4885DRD2 955/4885 |
| US-20140213586-A1 | VIRAL REPLICATION INHIBITORS | EIF2AK2, MAVS, ZC3HAV1 | TRIM24 462/4885TRIM33 448/4885DRD2 4549/4885 |
| US-20090318690-A1 | Benzisoxazole Compound | NR1I2, NR1I3, NR0B1 | TRIM24 1817/4885TRIM33 3304/4885DRD2 741/4885 |
| US-11279704-B2 | Viral replication inhibitors | EIF2AK2, MAVS, ZC3HAV1 | TRIM24 462/4885TRIM33 448/4885DRD2 4549/4885 |
| US-20220106321-A1 | VIRAL REPLICATION INHIBITORS | EIF2AK2, MAVS, ZC3HAV1 | TRIM24 462/4885TRIM33 448/4885DRD2 4549/4885 |
| US-11820766-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | TRIM24 4058/4885TRIM33 4330/4885DRD2 955/4885 |
| US-12012411-B2 | Viral replication inhibitors | EIF2AK2, MAVS, ZC3HAV1 | TRIM24 462/4885TRIM33 448/4885DRD2 4549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.